The UK pharma group fought Pfizer's $120 billion bid by promising growth. But its defence has been aided most by U.S. curbs on tax-driven M&A, says Reuters Breakingviews.
01:14
01:29
01:58
02:00
00:46
01:31
00:40
02:08
01:11
01:00
00:56
01:23
01:21
01:22
00:31
00:53
01:59
01:16
01:02
01:03
01:29
02:00
01:39
01:16
01:21
01:21
01:28
01:18
02:20
01:09
01:26
01:10
01:18
01:22
01:01
01:31
01:04
01:33
02:03
01:18
00:54
01:37
00:49
01:00
01:23
02:12
01:02
01:40
00:32
01:47
01:19
01:57
01:51
00:28
01:24
01:12
01:02
01:41
01:02
01:22
01:38
00:43
00:44
01:10
01:05
01:38
01:00
01:32
01:37
01:21
01:14
01:58
01:31
01:39
00:55
00:52
01:28
01:46
01:57
01:21
00:46
00:58
01:22
01:33
01:12
01:43
00:39
02:11
02:17
00:45
01:48
01:35
01:06
01:46
02:20
01:01
01:13
01:10
01:00
01:50
01:21
01:22
02:18
01:16
01:42
01:42
01:25
01:27
02:27
02:27
01:30
01:51
01:43
01:07
00:44
02:27
01:29
00:52
02:00
02:00